Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Completed · Phase 2
Conditions studied: Pancreatic Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genistein may help gemcitabine and erlotinib kill more tumor cells by making tumor cells more sensitive to the drugs. PURPOSE: This phase II trial is studying how well giving genistein together with gemcitabine and erlotinib works in treating patients with locally advanced or metastatic pancreatic cancer.
Key facts
- Study ID
- NCT00376948
- Run by
- Barbara Ann Karmanos Cancer Institute
- People needed
- 20
- Starts
- 2005-05-01
- Expected to finish
- 2010-03-01
- Last updated by the study team
- 2021-03-01
Who can join
Age: 21 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
- M. D. Anderson Cancer Center at University of Texas — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.